Payment overview · 2025
General Payments
$64,335.67
177 reported records · 27 companies
Healthcare provider profile · identity verified
Brian Steingo, MD
Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Neurology · BOCA RATON, FL · NPI 1417907163
Verified facts
What the public records show
CMS Open Payments records show Brian Steingo, MD received $64,335.67 in general payments during 2025 across 177 reported records.
EMD Serono, Inc. accounted for 45.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 37 associated products.
Alexion Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIRIS as an associated drug or biological on 303 records involving 233 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Soliris by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MAYZENT as an associated drug or biological on 26 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Mayzent by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $29,047.65 | 45.1% | 42 | 2025 |
| Alexion Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $24,426.05 | 38.0% | 27 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $8,222.67 | 12.8% | 14 | 2025 |
| Biogen, Inc. | Unresolved — no canonical attribution shown | $718.70 | 1.1% | 19 | 2025 |
| Genentech, Inc. | Unresolved — no canonical attribution shown | $227.40 | 0.3% | 6 | 2025 |
| Mallinckrodt Hospital Products Inc. | Unresolved — no canonical attribution shown | $225.81 | 0.3% | 6 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $206.67 | 0.3% | 10 | 2025 |
| TG Therapeutics, Inc. | Unresolved — no canonical attribution shown | $165.53 | 0.3% | 6 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $151.19 | 0.2% | 7 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $125.76 | 0.2% | 5 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $109.05 | 0.2% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $108.53 | 0.2% | 3 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $100.81 | 0.2% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $79.03 | 0.1% | 4 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $69.78 | 0.1% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $50.24 | 0.1% | 2 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $42.46 | 0.1% | 2 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $39.54 | 0.1% | 2 | 2025 |
| Life Molecular Imaging Ltd | Unresolved — no canonical attribution shown | $33.38 | 0.1% | 1 | 2025 |
| ARGENX US, INC. | Unresolved — no canonical attribution shown | $32.48 | 0.1% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $29.08 | 0.1% | 1 | 2025 |
| Aucta Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $28.42 | 0.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.17 | 0.0% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $20.62 | 0.0% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $20.42 | 0.0% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $18.15 | 0.0% | 1 | 2025 |
| SCILEX PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.08 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $50,860.50 | 15 |
| Consulting Fee | $6,675.00 | 2 |
| Food and Beverage | $4,879.84 | 145 |
| Travel and Lodging | $1,808.78 | 13 |
| Education | $111.55 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Mavenclad Normalized: mavenclad |
Drug | EMD Serono, Inc. | $24,109.57 | 11 | 2025 |
Source payment records
|
|||||
| ULTOMIRIS Normalized: ultomiris |
Biological | Alexion Pharmaceuticals, Inc. | $20,809.10 | 23 | 2025 |
Source payment records
|
|||||
| TYSABRI Normalized: tysabri |
Biological | Biogen, Inc. | $362.13 | 13 | 2025 |
Source payment records
|
|||||
| Ocrevus Normalized: ocrevus |
Biological | Genentech USA, Inc., Genentech, Inc. | $285.31 | 8 | 2025 |
Source payment records
|
|||||
| VUMERITY Normalized: vumerity |
Drug | Biogen, Inc. | $239.88 | 13 | 2025 |
Source payment records
|
|||||
| ACTHAR Normalized: acthar |
Biological | Mallinckrodt Hospital Products Inc. | $225.81 | 6 | 2025 |
Source payment records
|
|||||
| Ocrevus Zunovo Normalized: ocrevus zunovo |
Biological | Genentech USA, Inc. | $197.05 | 4 | 2025 |
Source payment records
|
|||||
| BRIUMVI Normalized: briumvi |
Drug | TG Therapeutics, Inc. | $165.53 | 6 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $109.05 | 4 | 2025 |
Source payment records
|
|||||
| HYQVIA Normalized: hyqvia |
Biological | Takeda Pharmaceuticals U.S.A., Inc. | $108.53 | 3 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $100.81 | 5 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $92.53 | 4 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $85.78 | 3 | 2025 |
Source payment records
|
|||||
| Zilbrysq Normalized: zilbrysq |
Drug | UCB, Inc. | $82.03 | 4 | 2025 |
Source payment records
|
|||||
| KESIMPTA Normalized: kesimpta |
Drug | Novartis Pharmaceuticals Corporation | $79.03 | 4 | 2025 |
Source payment records
|
|||||
| PONVORY Normalized: ponvory |
Drug | Vanda Pharmaceuticals Inc. | $69.78 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $50.24 | 2 | 2025 |
Source payment records
|
|||||
| INGREZZA Normalized: ingrezza |
Drug | Neurocrine BioSciences, Inc. | $42.46 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $39.98 | 2 | 2025 |
Source payment records
|
|||||
| Rystiggo Normalized: rystiggo |
Drug | UCB, Inc. | $35.71 | 1 | 2025 |
Source payment records
|
|||||
| Nayzilam Normalized: nayzilam |
Drug | UCB, Inc. | $33.45 | 2 | 2025 |
Source payment records
|
|||||
| NEURACEQ Normalized: neuraceq |
Drug | Life Molecular Imaging Ltd | $33.38 | 1 | 2025 |
Source payment records
|
|||||
| VYVGART HYTRULO Normalized: vyvgart hytrulo |
Drug | ARGENX US, INC. | $32.48 | 1 | 2025 |
Source payment records
|
|||||
| UPLIZNA Normalized: uplizna |
Biological | Amgen Inc. | $29.08 | 1 | 2025 |
Source payment records
|
|||||
| Motpoly XR Normalized: motpoly xr |
Drug | Aucta Pharmaceuticals, Inc. | $28.42 | 1 | 2025 |
Source payment records
|
|||||
| LEQEMBI Normalized: leqembi |
Drug | Biogen, Inc. | $25.29 | 1 | 2025 |
Source payment records
|
|||||
| Evrysdi Normalized: evrysdi |
Drug | Genentech USA, Inc. | $23.33 | 1 | 2025 |
Source payment records
|
|||||
| AMPYRA Normalized: ampyra |
Drug | Merz Pharmaceuticals, LLC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| INBRIJA Normalized: inbrija |
Drug | Merz Pharmaceuticals, LLC | $23.27 | 1 | 2025 |
Source payment records
|
|||||
| AVONEX Normalized: avonex |
Biological | Biogen, Inc. | $22.72 | 1 | 2025 |
Source payment records
|
|||||
| NUPLAZID Normalized: nuplazid |
Drug | ACADIA Pharmaceuticals Inc | $22.40 | 1 | 2025 |
Source payment records
|
|||||
| PANZYGA Normalized: panzyga |
Biological | PFIZER INC. | $22.17 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $20.62 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $18.15 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $17.14 | 1 | 2025 |
Source payment records
|
|||||
| ZTLido Normalized: ztlido |
Drug | SCILEX PHARMACEUTICALS INC. | $14.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Alexion Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | SOLIRIS open payments reported associated product |
CMS Open Payments — General Payments 303 supporting records · 233 recipient NPIs · example record 1202913090 |
Soliris · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | MAYZENT open payments reported associated product |
CMS Open Payments — General Payments 26 supporting records · 26 recipient NPIs · example record 1200006493 |
Mayzent · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Gabapentin | Gabapentin | 166 | 43 |
| Baclofen | Baclofen | 128 | 46 |
| Copaxone | Glatiramer Acetate | 127 | 14 |
| Kesimpta Pen | Ofatumumab | 91 | 11 |
| Teriflunomide | Teriflunomide | 89 | 12 |
| Tizanidine Hcl | Tizanidine Hcl | 85 | 22 |
| Alprazolam | Alprazolam | 81 | 18 |
| Dalfampridine Er | Dalfampridine | 67 | 14 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 50 | suppressed |
| Diazepam | Diazepam | 46 | suppressed |
| Avonex Pen (4 Pack) | Interferon Beta-1a | 43 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 34 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 31 | suppressed |
| Amantadine | Amantadine Hcl | 28 | 11 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 27 | suppressed |
| Myrbetriq | Mirabegron | 25 | suppressed |
| Aubagio | Teriflunomide | 24 | suppressed |
| Modafinil | Modafinil | 24 | suppressed |
| Glatiramer Acetate | Glatiramer Acetate | 23 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 23 | suppressed |
| Pregabalin | Pregabalin | 23 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 23 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 22 | suppressed |
| Glatopa | Glatiramer Acetate | 21 | suppressed |
| Diphenhydramine Hcl | Diphenhydramine Hcl | 17 | suppressed |
| Prednisone | Prednisone | 17 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 16 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 15 | suppressed |
| Soliris | Eculizumab | 15 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 13 | suppressed |
| Ritalin | Methylphenidate Hcl | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Gamunex-C | Immune Globul G/Gly/Iga Avg 46 | 12 | suppressed |
| Mayzent | Siponimod | 12 | suppressed |
| Betaseron | Interferon Beta-1b | 11 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 11 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 11 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $64,335.67 · 177 records | EMD Serono, Inc. | ACTHAR, AMPYRA, AUSTEDO XR, AVONEX, BOTOX, BRIUMVI, DAYBUE, Evrysdi, HYQVIA, INBRIJA, INGREZZA, INSPIRE, KESIMPTA, KISUNLA, LEQEMBI, Mavenclad, Motpoly XR, NEURACEQ, NUPLAZID, Nayzilam, Ocrevus, Ocrevus Zunovo, PANZYGA, PONVORY, PURIFIED CORTROPHIN GEL, QULIPTA, Rystiggo, TYSABRI, UBRELVY, ULTOMIRIS, UPLIZNA, VUMERITY, VYEPTI, VYVGART HYTRULO, Xeomin, ZTLido, Zilbrysq | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with Alexion Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error